1.Research progress on the regulation of JNK signaling pathway by traditional Chinese medicine for intervention in central nervous system diseases
Hongwei WANG ; Mingliang QIAO ; Chenyi ZHAO ; Pei ZHU ; Zilong WEI ; Yi MENG
China Pharmacy 2026;37(2):257-262
The c-Jun N-terminal kinase (JNK) signaling pathway, a key member of the mitogen-activated protein kinase (MAPK) family, plays a central role in the pathogenesis and progression of central nervous system (CNS) diseases by regulating core biological processes such as apoptosis, inflammatory responses, synaptic plasticity, and autophagy. This article sorts out and analyzes relevant literature published domestically and internationally in recent years, summarizing the mechanisms of action of the JNK signaling pathway in common CNS diseases and the research progress in traditional Chinese medicine (TCM) interventions in CNS diseases through the regulation of the JNK signaling pathway. Studies have shown that active components of TCM, such as berberine, paeoniflorin, and astragaloside Ⅳ, as well as compound formulations like Heixiaoyao san, Ditan tang, and Buyang huanwu tang, can exert neuroprotective effects in various CNS disorders, including Alzheimer’s disease, Parkinson’s disease, cerebral ischemia-reperfusion injury, and epilepsy, by inhibiting the aberrant activation of the JNK signaling pathway, thereby alleviating neuroinflammation, oxidative stress, and neuronal apoptosis, while improving synaptic function and cognitive behavioral deficits, regulating autophagy, and maintaining blood-brain barrier integrity.
2.Research progress of Qifu yin in the treatment of Alzheimer’s disease with marrow-sea insufficiency syndrome
Zilong WEI ; Chenyi ZHAO ; Mingliang QIAO ; Hongwei WANG ; Pei ZHU ; Yi MENG
China Pharmacy 2026;37(10):1376-1380
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder. Marrow-sea insufficiency serves as the fundamental basis for the onset of AD. Early syndrome differentiation-based intervention helps to delay disease progression, and improve patients’ cognitive function. Qifu yin is a representative specialized prescription for AD with marrow-sea insufficiency syndrome. Studies demonstrate that Qifu yin exerts neuroprotective effects through multiple pathways, including inhibiting the abnormal deposition of amyloid β -protein and hyperphosphorylation of tau protein, alleviating neuroinflammation, regulating oxidative stress and mitochondrial dysfunction, modulating the cholinergic system, and improving synaptic plasticity. Qifu yin combined with Western medicine such as donepezil, memantine, and butylphthalide, or combined with external therapies such as acupuncture, can effectively improve cognitive function and activities of daily living in AD patients with favorable safety. Future research should focus on the core pathogenesis and key targets of AD with marrow-sea insufficiency syndrome, provide in-depth elucidation of the scientific connotation of Qifu yin’s “tonifying the kidney to produce marrow”, and further conduct high-quality clinical studies to provide scientific evidence for the prevention and treatment of AD with marrow-sea insufficiency syndrome.
3.Fangxia Dihuang Formula regulates PERK/eIF2α axis-mediated microglial polarization in treatment of breast cancer complicated by depression.
Hong-Qiao FAN ; Ying-Yi FAN ; Xiao-Hua PEI
China Journal of Chinese Materia Medica 2025;50(14):4015-4025
Study on the mechanism of Fangxia Dihuang Formula(FXDH) in treating breast cancer complicated with depression through the regulation of M1/M2 microglial polarization via the PERK/eIF2α axis. In addition to control group and 4T1 group, a mouse model of breast cancer complicated with depression was established using 4T1 cells combined with corticosterone. The mice were divided into model group, PERK/eIF2α signaling axis agonist(CCT020312, 2 mg·kg~(-1)·d~(-1)) group, CCT020312(2 mg·kg~(-1)·d~(-1)) + FXDH(13.65 g·kg~(-1)·d~(-1)) group, FXDH(13.65 g·kg~(-1)·d~(-1)) group, FXDH(13.65 g·kg~(-1)·d~(-1)) + Capecitabine Tablets(CAP, 390 mg·kg~(-1)·d~(-1)) group, and Fluoxetine Hydrochloride Capsules(FXT, 2.6 mg·kg~(-1)·d~(-1)) + CAP(390 mg·kg~(-1)·d~(-1)) group, with continuous intervention for 21 d. Depression-like behaviors in mice were assessed through sugar preference test and open field test. Hematoxylin-eosin(HE) staining was used to evaluate the morphology of tumor and hippocampal DG region neurons. Nissl staining was employed to detect changes in Nissl bodies in the hippocampal CA3 region. Immunofluorescence was used to observe cluster of differentiation 86(CD86)/ionized calcium-binding adapter molecule 1(Iba-1) and cluster of differentiation 206(CD206)/Iba-1 in hippocampal tissue. Real-time fluorescence quantitative polymerase chain reaction(RT-qPCR) was used to detect the mRNA expression of M1-type microglia [interleukin-6(IL-6), tumor necrosis factor-α(TNF-α)] and M2-type [arginase-1(Arg-1), IL-10] in hippocampal tissue. Western blot was used to detect the protein expression of key factors in the PERK/eIF2α axis, including PERK, eIF2α, activating transcription factor 4(ATF4), and C/EBP homologous protein(CHOP) in hippocampal tissue. The results showed that compared to model group/CCT020312 + FXDH group, FXDH group increased sugar preference index, total movement distance, central zone distance, and central zone entries; reduced tumor mass and volume; tumor cells were sparsely arranged, with a smaller nuclear-to-cytoplasmic ratio and reduced nuclear division figures, increased Nissl body count, and alleviated neuronal nuclear pyknosis; increased CD206-positive M2-type microglia expression, decreased CD86/Iba-1-positive M1-type microglia expression; reduced IL-6 and TNF-α mRNA expression, and increased Arg-1 and IL-10 mRNA expression; downregulated PERK, eIF2α, ATF4, and CHOP protein expression levels. The results indicate that the mechanism of FXDH in treating breast cancer complicated with depression may be related to inhibiting the activity of the PERK/eIF2α axis, reducing the proportion of M1-type microglia, increasing the proportion of M2-type microglia, thereby suppressing neuronal immune inflammation, improving depressive symptoms, and subsequently delaying the progression of breast cancer.
Animals
;
Drugs, Chinese Herbal/administration & dosage*
;
Female
;
Microglia/cytology*
;
Mice
;
Depression/complications*
;
eIF-2 Kinase/genetics*
;
Humans
;
Breast Neoplasms/psychology*
;
Eukaryotic Initiation Factor-2/genetics*
;
Mice, Inbred BALB C
;
Signal Transduction/drug effects*
;
Cell Line, Tumor
4.Mechanism of puerarin improving myocardial contractile function in myocardial hypertrophy by inhibiting ferroptosis via Nrf2/ARE/HO-1 signaling pathway.
Yan-Dong LIU ; Wei QIAO ; Zhao-Hui PEI ; Guo-Liang SONG ; Wei JIN ; Wei-Bing ZHONG ; Qin-Qin DENG
China Journal of Chinese Materia Medica 2025;50(16):4679-4689
This study aims to explore the specific mechanism by which puerarin inhibits ferroptosis and improves the myocardial contractile function in myocardial hypertrophy through the nuclear factor erythroid 2-related factor 2(Nrf2)/antioxidant response element(ARE)/heme oxygenase-1(HO-1) signaling pathway. The hypertrophic cardiomyocyte model was established using phenylephrine, and H9c2 cells were divided into control group, model group, puerarin group, and puerarin+ML385 group. Cell viability and surface area were detected by cell counting kit-8(CCK-8) and immunofluorescence experiments. The mitochondrial membrane potential and Ca~(2+) concentration were measured. The ferroptosis-related indicators were detected by biochemical and fluorescence staining methods. The expression of proteins related to ferroptosis and the Nrf2/ARE/HO-1 signaling pathway was detected by Western blot. A myocardial hypertrophy model was established, and 40 rats were randomly divided into sham group, model group, puerarin group, and puerarin+Nrf2 inhibitor(ML385) group, with 10 rats in each group. Echocardiogram, hemodynamic parameters, and myocardial hypertrophy parameters were measured. Histopathological changes of myocardial tissues were observed by hematoxylin and eosin(HE) staining and Masson staining. Biochemical methods, enzyme-linked immunosorbent assay(ELISA), and fluorescence staining were used to detect inflammatory factors and ferroptosis-related indicators. Immunohistochemistry was used to detect the expression of proteins related to ferroptosis and the Nrf2/ARE/HO-1 signaling pathway. Cell experiments showed that puerarin intervention significantly enhanced the viability of hypertrophic cardiomyocytes, reduced their surface area, and restored mitochondrial membrane potential and Ca~(2+) homeostasis. Mechanism studies revealed that puerarin promoted Nrf2 nuclear translocation, upregulated the expression of HO-1, solute carrier family 7 member 11(SLC7A11), and glutathione peroxidase 4(GPX4), and decreased malondialdehyde(MDA), reactive oxygen species(ROS), and iron levels. These protective effects were reversed by ML385. In animal experiments, puerarin improved cardiac function in rats with myocardial hypertrophy, alleviated myocardial hypertrophy and fibrosis, inhibited inflammatory responses and ferroptosis, and promoted nuclear Nrf2 translocation and HO-1 expression. However, combined intervention with ML385 led to deterioration of hemodynamics and a rebound in ferroptosis marker levels. In conclusion, puerarin may inhibit cardiomyocyte ferroptosis through the Nrf2/ARE/HO-1 signaling pathway, thereby improving myocardial contractile function in myocardial hypertrophy.
Animals
;
NF-E2-Related Factor 2/genetics*
;
Rats
;
Ferroptosis/drug effects*
;
Signal Transduction/drug effects*
;
Isoflavones/pharmacology*
;
Male
;
Rats, Sprague-Dawley
;
Cardiomegaly/genetics*
;
Myocytes, Cardiac/metabolism*
;
Antioxidant Response Elements/drug effects*
;
Myocardial Contraction/drug effects*
;
Heme Oxygenase-1/genetics*
;
Cell Line
5.Synaptic Vesicle Glycoprotein 2A Slows down Amyloidogenic Processing of Amyloid Precursor Protein via Regulating Its Intracellular Trafficking.
Qian ZHANG ; Xiao Ling WANG ; Yu Li HOU ; Jing Jing ZHANG ; Cong Cong LIU ; Xiao Min ZHANG ; Ya Qi WANG ; Yu Jian FAN ; Jun Ting LIU ; Jing LIU ; Qiao SONG ; Pei Chang WANG
Biomedical and Environmental Sciences 2025;38(5):607-624
OBJECTIVE:
To reveal the effects and potential mechanisms by which synaptic vesicle glycoprotein 2A (SV2A) influences the distribution of amyloid precursor protein (APP) in the trans-Golgi network (TGN), endolysosomal system, and cell membranes and to reveal the effects of SV2A on APP amyloid degradation.
METHODS:
Colocalization analysis of APP with specific tagged proteins in the TGN, ensolysosomal system, and cell membrane was performed to explore the effects of SV2A on the intracellular transport of APP. APP, β-site amyloid precursor protein cleaving enzyme 1 (BACE1) expressions, and APP cleavage products levels were investigated to observe the effects of SV2A on APP amyloidogenic processing.
RESULTS:
APP localization was reduced in the TGN, early endosomes, late endosomes, and lysosomes, whereas it was increased in the recycling endosomes and cell membrane of SV2A-overexpressed neurons. Moreover, Arl5b (ADP-ribosylation factor 5b), a protein responsible for transporting APP from the TGN to early endosomes, was upregulated by SV2A. SV2A overexpression also decreased APP transport from the cell membrane to early endosomes by downregulating APP endocytosis. In addition, products of APP amyloid degradation, including sAPPβ, Aβ 1-42, and Aβ 1-40, were decreased in SV2A-overexpressed cells.
CONCLUSION
These results demonstrated that SV2A promotes APP transport from the TGN to early endosomes by upregulating Arl5b and promoting APP transport from early endosomes to recycling endosomes-cell membrane pathway, which slows APP amyloid degradation.
Amyloid beta-Protein Precursor/genetics*
;
Membrane Glycoproteins/genetics*
;
Animals
;
Protein Transport
;
Nerve Tissue Proteins/genetics*
;
Humans
;
Mice
;
Endosomes/metabolism*
;
trans-Golgi Network/metabolism*
6.Therapeutic development strategies for modulating GLI1-DNA interactions
Zhenyu QIAO ; Yongfu LUO ; Yaoye PEI ; Xiangyang LI ; Mengchen LU
Journal of China Pharmaceutical University 2025;56(4):432-443
The Hedgehog (Hh) signaling pathway is a critical transduction system regulating cell proliferation, differentiation, and tissue homeostasis during embryonic development. Its aberrant activation is closely associated with the pathogenesis of malignancies such as basal cell carcinoma and medulloblastoma. Although Smoothened (SMO)-targeting inhibitors have received clinical approval, their therapeutic efficacy is limited by acquired resistance mutation and compensatory pathway activation. Glioma-associated oncogene homolog 1 (GLI1), the terminal effector transcription factor of the Hh pathway, has emerged as a promising therapeutic target due to its tumor-specific overexpression and lower propensity for resistance induction. However, GLI1 is classified as an "undruggable" target due to the absence of well-defined ligand-binding pockets, low inhibitory activity, and poor drug-like properties. Currently, no GLI1 inhibitor has entered clinical trials. This review systematically analyzes multidimensional modulation strategies (e.g., allosteric modulation, protein-protein interaction disruption, targeted protein degradation) for targeting transcription factors, based on the structural and functional features of GLI1-DNA interaction combined with recent advances in structural biology and chemical biology, offering new paradigms to overcome therapeutic barriers against undruggable targets.
7.Study on the effect of PCSK9 inhibitor combined with atorvastatin on carotid atherosclerosis and its anti-inflammatory effect in patients with hypertension complicated with type 2 diabetes mellitus
Xiaoying XIONG ; Wei QIAO ; Weibing ZHONG ; Fei TU ; Fang WU ; Fangfang ZHENG ; Guoliang SONG ; Zhaohui PEI ; Yandong LIU
Chongqing Medicine 2025;54(5):1161-1165,1171
Objective To explore the effect of PCSK9 inhibitor combined with atorvastatin on carotid atherosclerosis and its anti-inflammatory effect in patients with hypertension complicated with type 2 diabetes mellitus.Methods A total of 100 patients with hypertension complicated with type 2 diabetes mellitus who were treated in Nanchang Third Hospital from October 2022 to August 2023 were selected as the research subjects.They were divided into the control group and the study group by the random number table method,with 50 cases in each group.Both groups of patients received conventional antihypertensive,hypoglycemic,and antiplatelet therapy.The control group took 20 mg of atorvastatin calcium tablets orally,once a night.On the basis of the control group,the study group was additionally given 150 mg of evolocumab injection(a PCSK9 inhibitor)by subcutaneous injection,once every two weeks.Both groups of patients were followed up for 24 weeks.The levels of blood lipids,blood glucose,inflammatory cytokines,carotid intima-media thickness(IMT),atherosclerotic plaque score and adverse reactions of the patients in the two groups before and after treatment were detected and compared.Results The levels of TC,TG and LDL-C in the study group after treatment were lower than those before treatment and those in the control group at the same period,and the differences were statistically significant(P<0.05).The levels of IL-1,IL-6,TNF-α,hs-CRP,as well as the ca-rotid IMT and atherosclerotic plaque score in the study group after treatment were lower than those before treatment and those in the control group at the same period,and the differences were statistically significant(P<O.05).During the treatment period,there was no significant difference in the occurrence of adverse reac-tions between the two groups(P>0.05).Conclusion The combination of PCSK9 inhibitor and atorvastatin can effectively regulate the blood lipid levels of patients with hypertension complicated and type 2 diabetes mellitus,alleviate the inflammatory response,and improve the degree of carotid atherosclerosis in these pa-tients.
8.Epidemiological survey of knee osteoarthritis and analysis of related risk factors among military personnel in plateau regions
Pei-Jie LI ; Yong-Jie QIAO ; Ya-Fei CAO ; Jian-Kang ZENG ; Fei TAN ; Jia-Huan LI ; Rui-Ling XU ; Shuo YE ; Sheng-Hu ZHOU
Medical Journal of Chinese People's Liberation Army 2025;50(11):1374-1381
Objective To investigate the epidemiological characteristics of knee osteoarthritis(KOA)among military personnel in plateau regions and to explore its risk factors.Methods From July 2023 to July 2024,a multi-stage stratified cluster random sampling method was employed to survey the prevalence of KOA and related risk factors among military personnel in the northwest plateau regions of China,covering different altitudes(1500-4500 m)and geographical areas(Gansu,Qinghai,Tibet,and Xinjiang).All study subjects were divided into KOA and non-KOA groups based on the presence or absence of KOA.Variables including age,gender,body mass index(BMI),education level,smoking status,military rank,military branch,service duration,regional altitude,annual average temperature,training duration,perceived training intensity,and history of knee injury were selected for univariate analyses between groups.Variables with P<0.05 in the univariate analyses were included in the binary multifactor logistic regression to identify risk factors for KOA.Results A total of 3000 questionnaires were distributed,and 2854 valid questionnaires were collected,with a response rate of 95.13%.The sample included 2584 males and 270 females,with 510 cases of KOA,resulting in a prevalence rate of 17.9%.Univariate analysis showed that there were statistically significant differences between KOA and non-KOA groups in terms of age,BMI,smoking status,military rank,military branch,service duration,regional altitude,annual average temperature,training duration,perceived training intensity,and history of knee injury(P<0.05).However,no significant differences were found in gender and education level(P>0.05).Binary multivariate logistic regression analysis revealed that older age(OR=1.382,P=0.017),higher BMI(P<0.01),smoking(OR=1.929,P<0.01),higher military rank(OR=1.485,P=0.007),being a member of the Armed Police(P<0.01),longer service duration(P<0.01),higher regional altitude(OR=1.459,P<0.01),lower annual average temperature(OR=1.188,P=0.001),longer training duration(P<0.01),higher perceived training intensity(OR=2.450,P<0.01),and history of knee injury(OR=2.768,P=0.002)were independent risk factors for KOA.Conclusions Older age,overweight/obesity,smoking,higher military rank,being a member of the Armed Police,longer service duration,higher altitude,cold climate,longer training duration,higher training intensity,and history of knee injury are independent risk factors for KOA among military personnel in the northwest plateau regions of China.
9.Advances in DNA methylation of brain-derived neurotrophic factor and depression
Zi-yun LIAO ; Meng-yu WANG ; Jing-yi QIAO ; Run ZHANG ; Pei-dong LIU ; Xin-wang CHEN
Chinese Pharmacological Bulletin 2025;41(5):825-829
Depression is a heterogeneous mental disorder in which the interaction between genetic susceptibility and environ-mental factors plays a key role in its pathogenesis.Although the specific mechanisms of the disease still need to be thoroughly studied and elucidated,there is now a broad consensus that epi-genetic markers have a central influence on its mechanism of ac-tion.DNA methylation of brain-derived neurotrophic factor(BD-NF)is not only regarded as a promising epigenetic biomarker of pathology,but may also help predict the efficacy of antidepres-sants.In this paper we reviewed the gene structure of BDNF and its DNA methylation regulation mechanism,and also analyzed the changes of DNA methylation of this factor in depression pa-tients and animal models,aiming to provide new ideas and theo-retical support for clinical research.
10.One case of epileptic-like seizures induced by isavuconazole
Chinese Journal of Pharmacoepidemiology 2025;34(1):116-120
A 37-year-old patient with pulmonary mucormycosis who developed epileptic-like seizures during treatment with isavuconazole.The patient had multiple comorbidities,including hypoalbuminemia,hepatic dysfunction,and renal insufficiency and displayed normal mental status before treatment.However,after 27 days of isavuconazole therapy,the patient experienced a sudden onset of unresponsiveness,absence seizures,and body rigidity.Therapeutic drug monitoring revealed a plasma trough concentration of isavuconazole at 6.4 mg·L-1,the epileptic-like seizures were suspected to be caused by neurotoxicity due to elevated isavuconazole plasma levels.The drug was immediately discontinued,and no further seizures occurred.The Naranjo's Assessment Scale was used to evaluate the association between adverse reactions and isavuconazole,and the result was"probably relevant".This case highlights the need for caution regarding the potential adverse reaction of seizures when using isavuconazole in clinical practice.This case suggests that clinical use of isavuconazole should be auompanied by vigilance epileptic-like adverse events.Pharmaceutical care and timely analysis of medication use should be carried out,and appropriate symptomatic management should be provided promptly in case of any adverse events.

Result Analysis
Print
Save
E-mail